Thus, GLP-1 RAs are considered effective in promoting insulin secretion and inhibiting glucagon secretion by targeting most of the defects associated with the pathogenesis of T2DM [16]
One filing referenced distributors listing the drug as out-of-stock or available only in limited quantities, suggesting gaps in the supply chain despite the FDAs confidence in Eli Lillys manufacturing capacity
Furthermore, exendin-4 administration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in vivo animal model of PD has been shown to inhibit microglial activation thereby minimizing the loss of dopaminergic neurons in the pars compacta of the substantia nigra and the striatum [78]
Understanding why tirzepatide might stop working as expected can help differentiate between tolerance and other factors
The underlying science, that gut bacteria and SCFAs influence GLP-1, is real and well documented
However, this is not the only reason